Analystreport

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "buy" rating and a $97.00 price target on the

Iovance Biotherapeutics, Inc.  (IOVA) 
Last iovance biotherapeutics, inc. earnings: 2/25 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: iovance.com